The Latest Breaking News from Lilly

Eli Lilly delivered a promising update for its experimental obesity treatment over the weekend, leading LLY stock to pop Monday.

The ideal scenario for this Lilly stock option trade for the stock to stay between 300 and 335 for the next two weeks.

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) for severe alopecia areata (AA). If approved, Olumiant would be the first centrally-authorized oral treatment and first JAK inhibitor for severe AA in the European Union. …

A newly confirmed stock market rally immediately came under heavy pressure as Walmart and Target warnings slammed the major indexes.

The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.

Eli Lilly is the IBD Stock Of The Day after "transformative" data in obesity helped LLY stock retain its recent breakout.

With several core products showing strength, along with their Covid-19 antibodies, Eli Lilly updated their 2022 EPS guidance.

A market rally attempt is underway, but the major indexes lost ground. Apple and Facebook led key earnings. Elon Musk will buy Twitter.

Eli Lilly And Co (NYSE:LLY) reported topline results from SURMOUNT-1 Phase 3 trial evaluating Tirzepatide (5 mg, 10 mg, 15 mg) in obese patients with at least one comorbidity who do not have diabetes. Data exhibited that tirzepatide reduced patients' weights by an average of 16%, 21.4%, and 22.5% at the respective doses,…